Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment ...

Stock indexes recovered from early losses on Tuesday and finished higher mainly due to the strength of the Magnificent Seven stocks.  Stocks on Tuesday initially opened lower ahead of Wednesday's ...

The stock's fall snapped a two-day winning streak.

Hims stock surged Tuesday after the compounding pharmacy said it would sell Eli Lilly's branded weight-loss drug on its ...

Shares of Hims & Hers Health ( HIMS 5.01%) surged on Tuesday, closing the session up 5.25% after having been up by as much as ...

Hims & Hers Health (NYSE:HIMS) stock gains as the company adds Eli Lilly's (LLY) weight loss therapy tirzepatide & generic ...

The company’s stock rise reflects investor optimism following the news that Hims & Hers will provide both branded versions of ...

Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding tirzepatide, the active ingredient in Zepbound and ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $152.57, a high ...

Eli Lilly rolled out positive Phase 2 results for lepodisiran, a therapy targeting lipoprotein(a)—that genetic party crasher ...

Lately, however, Eli Lilly's stock has cooled. Shares have been essentially flat since July 2024. The market for GLP-1 ...